295 related articles for article (PubMed ID: 10410144)
21. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach.
Stipsanelli E; Valsamaki P
Hell J Nucl Med; 2005; 8(2):103-8. PubMed ID: 16142251
[TBL] [Abstract][Full Text] [Related]
23. Radioimmunodetection and radioimmunotherapy of malignant melanoma. A review.
Liewendahl K; Pyrhönen S
Acta Oncol; 1993; 32(7-8):717-21. PubMed ID: 8305217
[TBL] [Abstract][Full Text] [Related]
24. Imaging of pancreatic adenocarcinoma with radiolabeled monoclonal antibodies.
Mariani G
Ann Oncol; 1999; 10 Suppl 4():37-40. PubMed ID: 10436782
[TBL] [Abstract][Full Text] [Related]
25. [Immunoscintigraphy using radio-labeled monoclonal antibodies. Development of a method of cancer diagnosis and hopes for a new form of therapy].
Mach JP; Bischof-Delaloye A; Curchod S; Studer A; Grob JP; Volant JC; Mosimann F; Givel JC; Douglas P; Leyvraz S
Schweiz Med Wochenschr; 1987 Jul; 117(29):1076-86. PubMed ID: 3499666
[TBL] [Abstract][Full Text] [Related]
26. Current status of cancer immunodetection with radiolabeled human monoclonal antibodies.
De Jager R; Abdel-Nabi H; Serafini A; Pecking A; Klein JL; Hanna MG
Semin Nucl Med; 1993 Apr; 23(2):165-79. PubMed ID: 8511602
[TBL] [Abstract][Full Text] [Related]
27. [Immunotargeting of tumors: state of the art and prospects in 2000].
Pèlegrin A; Xavier F; Barbet J; Bartholeyns J; Baty D; Buchegger F; Chatal JF; Dufief F; Gurreau D; Gruaz-Guyon A; Lamotte D; Leserman L; Mach JP; Robert B; Saccavini JC; Teillaud JL; Teulon I
Bull Cancer; 2000 Nov; 87(11):777-91. PubMed ID: 11125287
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
[TBL] [Abstract][Full Text] [Related]
29. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
[TBL] [Abstract][Full Text] [Related]
30. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
31. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
Lindén O; Kurkus J; Garkavij M; Cavallin-Ståhl E; Ljungberg M; Nilsson R; Ohlsson T; Sandberg B; Strand SE; Tennvall J
Cancer Biother Radiopharm; 2005 Aug; 20(4):457-66. PubMed ID: 16114994
[TBL] [Abstract][Full Text] [Related]
32. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
33. Animal models for radiolabeled monoclonal antibodies in cancer research.
Aas M; Fjeld JG
Acta Oncol; 1993; 32(7-8):819-24. PubMed ID: 8305231
[TBL] [Abstract][Full Text] [Related]
34. Radioimmunodiagnosis and therapy.
Verhaar-Langereis MJ; Zonnenberg BA; de Klerk JM; Blijham GH
Cancer Treat Rev; 2000 Feb; 26(1):3-10. PubMed ID: 10660488
[TBL] [Abstract][Full Text] [Related]
35. Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies.
Goldenberg DM
Am J Gastroenterol; 1991 Oct; 86(10):1392-403. PubMed ID: 1656726
[TBL] [Abstract][Full Text] [Related]
36. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
[TBL] [Abstract][Full Text] [Related]
37. Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy.
Goldenberg DM
Semin Nucl Med; 1989 Oct; 19(4):332-9. PubMed ID: 2678484
[TBL] [Abstract][Full Text] [Related]
38. [Radioimmunologic targeting and therapy with antihuman primary hepatic cancer monoclonal antibodies (Hepama I) in patients].
Shi L; Wu M; Chen H
Zhonghua Zhong Liu Za Zhi; 1997 Mar; 19(2):146-9. PubMed ID: 10743083
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies: the promise and the reality.
Coons T
Radiol Technol; 1995; 67(1):39-60; quiz 61-4. PubMed ID: 7491408
[TBL] [Abstract][Full Text] [Related]
40. [Radioimmunotherapy of solitary liver metastases using intratumor instillation of 131I-labeled monoclonal antibodies--initial results of a clinical study].
Müller-Gärtner HW; Montz R; Klapdor R; Hirschmann M; Rehpenning W; Langkowski J
Nuklearmedizin; 1988 Dec; 27(6):258-65. PubMed ID: 3217256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
